CLL – Update from ASH 2022
Studies from ASH22 suggest a potential shift in the approach to treating CLL based on gene subtypes and the risk of infection, which is the primary cause of death during treatment. In this MEDtalk, Carsten Utoft Niemann, senior physician at the Department of Blood Diseases, Rigshospitalet, and chairman of the Nordic CLL group, will present some of these studies and give his professional opinion on how this new knowledge affects clinical practice and what further research is needed.
